Part of University Of California
Clinical Trials
807
78 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1905
Active, not recruiting
51
6.3%
Completed
504
62.5%
Enrolling By Invitation
11
1.4%
Not yet recruiting
16
2.0%
Recruiting
113
14.0%
Suspended
6
0.7%
Terminated
56
6.9%
Unknown
11
1.4%
Withdrawn
39
4.8%
No approval data available
- Novonesis is partnering with Metropolitan Community College in Omaha to shape a new biotechnology technician training program and launch the Novonesis Biomanufacturing Pathways Scholarship. - Nebraska bioscience employment grew 6.3% from 2019 to 2023, outpacing the state's 2.9% overall private-sector growth, underscoring demand for skilled workers. - The initiative includes a 15-week Biotechnology Fundamentals Microcredential, a Biotechnology Career Certificate, job shadowing, facility tours, and recruiter screening for graduates. - The Nebraska effort is part of a broader national strategy spanning K-12 outreach, community college partnerships, and university research collaborations across 14 North American sites.
- UC Davis researchers successfully treated cats with feline infectious peritonitis (FIP) using mesenchymal stromal cells combined with antiviral drugs, demonstrating enhanced immune recovery compared to antivirals alone. - The combination therapy reduced systemic inflammation and helped restore immune balance by decreasing overactive T and B cells while increasing regulatory T cells that calm the immune system. - FIP shares key features with COVID-19, including widespread inflammation and immune dysfunction, making this feline model valuable for understanding and potentially treating long COVID syndrome in humans. - The treatment showed no serious side effects and helped exhausted immune cells recover while potentially forming protective memory cells for future infections.
- Researchers at UC Davis created JRT, a novel compound derived from LSD by repositioning just two atoms in its molecular structure, potentially offering a breakthrough treatment for schizophrenia without hallucinogenic effects. - In preclinical studies, JRT demonstrated remarkable ability to regrow brain cells and repair neural pathways in mice, reducing negative schizophrenia symptoms like cognitive fog and social withdrawal. - The compound also exhibited potent antidepressant properties, proving to be 100 times more effective than ketamine at a fraction of the dose, suggesting broad therapeutic potential for mental health conditions.
- University of New Mexico researchers have developed a vaccine that generates antibodies against pathological tau protein (pT181), showing efficacy in both mice and non-human primates with strong immune responses. - The vaccine uses virus-like particles (VLPs) as a delivery platform, requiring only one primary shot and two boosters without adjuvants, demonstrating safety and durability in preclinical studies. - Researchers are now seeking funding to advance to Phase 1 human clinical trials, potentially offering a more effective approach than current amyloid beta-targeting treatments that show only modest effects on Alzheimer's progression.
- CRISPR-Cas9 targeting VEGFA delivered via AAV vectors reduces VEGF levels in monkeys, potentially treating choroidal neovascularisation (CNV). - Low AAV doses (6 x 1011 vg/eye) led to a 33% reduction in VEGF protein concentrations and decreased CNV severity. - High AAV doses (6 x 1012 vg/eye) resulted in significant retinal toxicity, including subfoveal deposits and outer retinal thinning. - Retinal damage appears linked to high Cas9 expression or AAV vector dose, not VEGFA gene editing itself, suggesting optimization is needed.
